Globe Newswire (Tue, 3-Feb 1:00 AM ET)
Globe Newswire (Wed, 7-Jan 1:00 AM ET)
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
Globe Newswire (Thu, 11-Dec 1:00 AM ET)
Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update
Globe Newswire (Thu, 4-Dec 1:00 AM ET)
Addex Therapeutics Schedules Q3 2025 Results Call as Key Pipeline Programs Advance
Market Chameleon (Mon, 1-Dec 3:38 AM ET)
Globe Newswire (Mon, 1-Dec 1:00 AM ET)
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
Addex Therapeutics - American Depositary Shares trades on the NASDAQ stock market under the symbol ADXN.
As of February 24, 2026, ADXN stock price was flat at $7.25 with 231 million shares trading.
ADXN has a market cap of $8.93 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ADXN traded as high as $45.60 and as low as $5.00.
ADXN has underperformed the market in the last year with a price return of -19.4% while the SPY ETF gained +16.3%. ADXN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -0.7% and -6.5%, respectively, while the SPY returned +3.1% and -0.7%, respectively.
ADXN support price is $6.67 and resistance is $7.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADXN shares will trade within this expected range on the day.